High-Dose Vitamin D Linked With Increased Risk of Fractures Among Older Women

Newswise — Women age 70 years or older who received a single annual high dose of vitamin D had a higher rate of falls and fractures compared to women who received placebo, according to a study in the May 12 issue of JAMA.

The results of studies investigating the effects of cholecalciferol (vitamin D) supplementation on falls and fractures have been incon¬sistent, with some meta-analyses indicating a reduced fracture risk, while others have concluded that vitamin D supplementation is ineffective, or may in¬crease the risk of fracture. For individuals attempting to modify their risk of falls or fractures via vitamin D, adherence to daily supplementation is typically poor, according to background information in the article.

Kerrie M. Sanders, Ph.D., of the University of Melbourne, Geelong, Australia and colleagues conducted a study to examine whether high-dose cho¬lecalciferol (500,000 IU) given orally once a year to older women would reduce falls and fractures. The vitamin D was given in a single, high-dose to address low adherence and to be a prac¬tical intervention easily translated to clinical practice. The trial included 2,256 community-dwelling women, ages 70 years or older, considered to be at high risk of fracture, who were recruited from June 2003 to June 2005 and were randomly assigned to receive 500,000 IU of cholecalciferol or placebo each autumn to winter for 3 to 5 years. The study concluded in 2008. The trial participants had a total of 5,404 falls over the study period, with 74 percent of 837 women in the vitamin D group and 68 percent of 769 women in the placebo group having at least 1 fall. Analysis indicated women in the annual high-dose vitamin D group experienced 15 percent more falls. Women in the vitamin D group had 171 fractures vs. 135 in the placebo group, with 26 percent more fractures for participants in the vitamin D group, who also had a 31 percent higher incidence of falls in the first 3 months following dosing.

“This is the first study to demon¬strate increased risk of falls associated with any vitamin D intervention and the second study to demonstrate an in¬creased fracture risk associated with annual high-dose vitamin D therapy in elderly women. Our study used the largest total annual dose of vitamin D (500,000 IU) reported in any large ran¬domized controlled trial, raising the possibility that the adverse outcome is dose-related. The opposing outcomes of 2 studies that used the same total annual dose (300,000 IU intramuscularly) suggest that the dosing regimen (i.e., 4 monthly vs. annually) rather than the total dose might determine the out¬come,” the authors write.

“This line of reasoning is sup¬ported by the temporal risk pattern that we observed and the fact that harm has not been reported in the numerous studies that have used more frequent dosing. Thus, it is reasonable to specu¬late that high serum levels of vitamin D or metabolites resulting from the large annual dose, subsequent de¬crease in the levels, or both might be causal. Furthermore, because the lev¬els of 25-hydroxycholecalciferol dem¬onstrated in this study could occur with other recommended dosing regi¬mens, the outcome of this study sug¬gests that safety of high-dose vitamin D supplementation warrants further study.”(JAMA. 2010;303[18]:1815-1822. Available pre-embargo to the media at www.jamamedia.org)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.

Editorial: High-Dose Vitamin D Supplementation - Too Much of a Good Thing?

Bess Dawson-Hughes, M.D., and Susan S. Harris, D.Sc.. of Tufts University, Boston, write in an accompanying editorial that the study by Sanders et al underscores the importance of continuing to improve understanding of basic vitamin D physiology, particularly as it relates to the increased variety of supplement forms that have become available by prescription and over-the-counter.

“Specifi¬cally, the effect of dose size, route (intramuscular vs. oral), and dosing interval on aspects of vitamin D metabolism including CYP24 activity and on local tissue-specific 1,25-dihydroxyvitamin D levels and actions should be investigated. It may also be necessary to reevaluate the risks and benefits of the current clinical practice of providing high loading doses of cholecalcif¬erol to patients who are vitamin D deficient. In the mean¬time, it is important to reiterate that although vitamin D insufficiency is widespread, it can be safely corrected with a variety of existing supplement types and regimens and it should continue to be identified and treated in clinical practice.”(JAMA. 2010;303[18]:1861-1862. Available pre-embargo to the media at www.jamamedia.org)

Editor’s Note: Please see the article for additional information, including financial disclosures, funding and support, etc.